BRAZIL · COMPANIES
Key Facts
- The country Brazil is Latin America’s largest economy, and its bankruptcy law lets a company agree a debt plan with creditors and then ask a judge to make it binding.
- Why it matters Oncoclínicas, Brazil’s largest private cancer-care network, is restructuring about US$1.05 billion of debt, and creditor backing decides whether the plan can bind everyone.
- Why now Creditors holding 61.6% of the covered debt backed the plan by Friday 30 October 2026, up from 29.79% on 29 October.
- What happened Creditors with more than R$3.5 billion (US$646 million) of claims have joined the plan, above the 50% minimum, and the company will now ask a São Paulo court to approve it.
- The numbers 61.6% backing, a covered base of about R$5.7 billion (US$1.05 billion), and a 30-day window for objections once the creditors’ notice is published.
- What it means for you Creditors face longer repayment schedules, possible convertible debentures, payment in company shares or discounts under the plan.
- Still open When the court will approve the plan, how many creditors will object, and how a separate fight over a buyout offer ends.
- Power Index Brazil ranks 1st of 14 in The Rio Times Latin America Power Index, with 75.0 points (October 2026 edition).
In Plain English
An extrajudicial recovery, or recuperação extrajudicial, is a Brazilian out-of-court restructuring in which a company agrees a plan with its creditors and then asks a judge to approve it. Approval, called homologation, makes the plan binding on the company and the creditors it covers.
The edital is a public notice published once enough creditors have joined, and it opens a window for other creditors to object. The CVM is the Brazilian securities regulator.
Oncoclínicas, Brazil’s largest private cancer-care network, disclosed on Friday 30 October 2026 that creditors holding 61.6% of its covered debt have backed its out-of-court restructuring plan, according to g1 and Folha. The backers hold more than R$3.5 billion (US$646 million) of claims in a base of about R$5.7 billion (US$1.05 billion), converted at the Brazilian central bank rate of R$5.4212 per US$ on 30 October.
Support stood at 29.79% in the company’s filing of Thursday 29 October, so the share more than doubled in a day and now clears the 50% minimum quorum cited by g1. The company will now ask the São Paulo court to approve the plan, the step that makes it binding on the creditors it covers.
What the Plan Offers Creditors
The updated plan filed on 23 October gives each creditor options that include replacing part of the claims with new debt, stretching the repayment schedule, receiving assets in lieu of cash, taking convertible debentures, being paid in part with company shares, or accepting a discount. Special terms apply to suppliers that keep trading with the company, according to the filing.
The company says the process does not cover obligations created after the filing date, including current obligations to customers and suppliers, and that its clinics keep treating patients normally. The covered base of about R$5.7 billion (US$1.05 billion) excludes claims between companies of the group.
What Happens Next in Court
The case number is 4126842-40.2026.8.26.0100, before the 3rd Bankruptcy and Judicial Reorganization Court of São Paulo. The company filed a further updated version of the plan there on 29 October, with wording adjustments that it says do not materially change the economics.
Under Article 164 of Brazil’s bankruptcy law, as cited in the filing, a notice is published to call creditors, who then have 30 days to file objections before the court considers approving the plan. The news site g1 reported that the next step is publication of that notice, after which any creditor can challenge the plan.
The Company Behind the Plan
Folha described Oncoclínicas as Brazil’s largest private cancer-treatment network, with 142 units in 49 cities, and said its market value reached US$1.87 billion after its 2021 share offering and its share price has since fallen more than 85%. The company asked for the extrajudicial recovery in July 2026, as covered in the earlier report on its US$1 billion debt plan.
Folha also reported a second-quarter net loss of R$475.7 million (US$87.7 million), against R$142.3 million (US$26.2 million) a year earlier, with net revenue down 28.5% to about R$1.1 billion (US$203 million). Those figures frame the financial pressure behind the restructuring.
A Separate Fight Over a Buyout Offer
A federal court in São Paulo provisionally suspended on 23 October the enforceability of a CVM board decision requiring a public offer to buy the company’s shares under Article 39 of its bylaws, according to the company’s filing of 28 October. The action was brought by the fund Josephina III, which Valor Econômico described as controlled by the asset manager Centaurus.
The company cancelled the shareholder meeting set for 3 November, requested by three shareholder funds including Latache IV and Latache MHF I, because the court decision removed its purpose, and it stressed that it is not a party to the case. Valor Econômico reported that the offer could reach R$14 billion (US$2.6 billion), a figure the company quoted in a communiqué of 27 October, and the earlier report on the CVM ruling explains the dispute.
What It Means for You
For US investors who hold Brazilian credit or Oncoclínicas shares, the plan points to longer maturities, possible conversion into debentures or shares and discounts, and the court step still has to bind creditors who did not sign. The wider Brazil business coverage follows other companies that use the same out-of-court route.
Patients are not directly affected, since the company says its clinics operate normally and the restructuring does not cover its current operating obligations. The next visible milestone is the publication of the creditors’ notice and the start of the 30-day objection window.
What Is Not Known
It is not known when the creditors’ notice will be published or how many creditors will object during the 30-day window. The filings give no date for court approval.
How the buyout-offer dispute ends is also open, because the federal court’s decision is provisional and the CVM ruling remains under challenge. It is also unclear how the new debentures and share payments would change the ownership of the company.
Frequently Asked Questions
What is Oncoclínicas?
Oncoclínicas is Brazil’s largest private cancer-care network, with 142 units in 49 cities, according to Folha. Its shares trade on the São Paulo stock exchange under the ticker ONCO3.
How much debt is Oncoclínicas restructuring?
The covered base is about R$5.7 billion (US$1.05 billion), excluding claims between group companies. Creditors holding more than R$3.5 billion (US$646 million) had joined the plan by 30 October.
What is an extrajudicial recovery in Brazil?
It is an out-of-court restructuring in which a company agrees a plan with creditors and then asks a judge to approve it. Once approved, the plan binds the company and the creditors it covers.
Are Oncoclínicas patients affected by the restructuring?
The company says its clinics keep operating normally. The plan does not cover obligations created after the filing date, including current obligations to customers and suppliers.
Sources: Oncoclínicas, Fato Relevante, 23 October 2026; Oncoclínicas, Fato Relevante, 29 October 2026; Oncoclínicas, Fato Relevante and Aviso aos Acionistas, 28 October 2026; Oncoclínicas, Comunicado ao Mercado, 27 October 2026; g1, 30 October 2026; Folha, 30 October 2026; Banco Central do Brasil, PTAX 30 October 2026.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Brazil runoff, Sunday, October 25: Brazil runoff start time and results schedule. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.